Previous 10 | Next 10 |
PAVmed and Lucid Diagnostics to Participate in Panel Presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference PR Newswire NEW YORK , Sept. 21, 2023 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), a diversified commercial-stage...
Lucid Diagnostics Releases Positive Data from First Prospective Clinical Utility Study of EsoGuard® Esophageal Precancer Detection PR Newswire Multicenter observational study documents excellent concordance of EsoGuard results with subsequent medical decision-making by mu...
Lucid Diagnostics Releases Positive Data Demonstrating Clinical Utility of EsoGuard® Esophageal Precancer Detection in Fire Fighters PR Newswire Study documents 100 percent concordance between EsoGuard ® test results and subsequent medical decision-making ...
2023-08-31 20:45:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Lucid Diagnostics Executes First Direct Employer Contract to Provide EsoGuard® Esophageal Precancer Testing as an Employee Benefit PR Newswire EsoGuard Testing now incorporated in Texas -based Ancira Auto Group's corporate Health and Wellness Program NEW YOR...
2023-08-16 17:18:07 ET PAVmed Inc. (PAVM) Q2 2023 Earnings Conference Call August 16, 2023, 08:30 AM ET Company Participants Michael Parks - Vice President of Investor Relations Lishan Aklog - Chairman and Chief Executive Officer Dennis McGrath - Executive Vice P...
PAVmed Provides Business Update and Second Quarter Financial Results PR Newswire EsoGuard ® test volume continues to grow as Lucid makes strides with commercial expansion and additional supporting data Veris Health prepares to launch the next generation of the...
2023-08-15 16:12:25 ET PAVmed press release ( NASDAQ: PAVM ): Q2 Non-GAAP EPS of -$0.23 misses by $0.08 . Revenue of $0.2M misses by $0.75M . Lucid had cash and cash equivalents of $32.6 million as of June 30, 2023, compared to $39.5 million as of March 31, 202...
Lucid Diagnostics Provides Business Update and Second Quarter Financial Results PR Newswire Quarterly EsoGuard ® test volume increased 20 percent sequentially and 159 percent annually Revenue cycle management upgrade completed with immediate positive impact to...
2023-08-03 02:15:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
News, Short Squeeze, Breakout and More Instantly...
Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume PR Newswire Quarterly EsoGuard ® test volume increased 31 percent sequentially NEW YORK , July 23, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("L...
Lucid Diagnostics Launches New Corporate Website PR Newswire NEW YORK , July 11, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-ow...
Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population PR Newswire Prospective screening study demonstrates excellent EsoGuard s...